OBI Pharma 2024 Materiality Analysis of Stakeholder Concerns
Prioritization of Major Themes
After cross-analyzing stakeholder concerns with the significance of operational impacts, OBI Pharma selected the following 12 material topics for 2024. The prioritization of material topics has been adjusted compared with 2023, as shown in the table below:
| 2023 | 2024 | Changes |
|---|---|---|
| Product Research and Development Innovation | Innovation and R&D | – |
| Clinical Trials and Subsequent Development | Stakeholder Engagement | Added |
| Intellectual Property Protection | Talent Recruitment and Retention | Added |
| Information Disclosure | Corporate Governance | Added |
| Economic Performance | Financial Performance | – |
| Customer Health and Safety | Risk Management | Added |
| Occupational Health and Safety | Labor Relations | ↑1 |
| Labor-Management Relations | Career Development and Training | ↑2 |
| Training and Education | Employee Compensation and Benefits | Added |
| Ethical Conduct and Code of Practice | Added | |
| Information Security | Added |